With a 90-minute onset of action and 24-hour duration of action, patients with type 1 DM (T1DM) or type 2 DM (T2DM) receiving insulin glargine may have lower risk of hypoglycemia, particularly nocturnal hypoglycemia, compared with intermediate-acting human insulin such as neutral protamine Hagedorn [3–5]. Here, INS is linked to Hypoglycemia.